Serum Institute

Serum Institute to produce additional 100 million COVID-19 vaccine doses for India, other countries

Its latest collaboration along with Gavi and the Bill and Melinda Gates Foundation brings the total number of vaccine doses to be covered to an aggregate of up to 200 million doses.

published on : 29th September 2020

Will Centre have Rs 80,000 crore for distribution of COVID-19 vaccine, asks Serum Institute CEO

The central health ministry official said that they have not received any official proposal from the institute regarding mass production, procurement, and distributions of the vaccine.

published on : 26th September 2020

Phase-III human clinical trial of Oxford COVID-19 vaccine begins in Pune

Under phase-II, trials had been conducted at the Bharti Vidyapeeth Medical College and also KEM Hospital in the city.

published on : 21st September 2020

Phase-III trial of Oxford vaccine to begin in Pune next week

Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city.

published on : 20th September 2020

Serum Institute of India gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine

SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.

published on : 16th September 2020

Will resume COVID-19 vaccine trials after DCGI nod: Serum Institute

The human trials resumed days after a pause had been announced in the trials after an adverse reaction in one of the participants.

published on : 12th September 2020

DCGI orders Serum Institute of India to suspend recruitment for Oxford COVID-19 vaccine trials

Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study

published on : 12th September 2020

'Reviewing situation': Serum Institute pauses COVID-19 vaccine trials in India after DCGI notice

The drug regulator's move comes after AstraZeneca, which is developing the vaccine candidate against COVID-19 with researchers of Oxford University

published on : 10th September 2020

Will adhere to DCGI instructions: Serum Institute on show cause over not pausing trial of COVID-19 vaccine

The Serum Institute said in its statement that they were not instructed to pause trials.

published on : 10th September 2020

DCGI sends show-cause notice to Serum Institute for not pausing trial of COVID-19 vaccine

The drug regulator's move comes after AstraZeneca, which is developing the vaccine candidate against COVID-19 with researchers of Oxford University

published on : 9th September 2020

India will continue Oxford vaccine trial, says Serum Institute after illness in volunteer pauses trial abroad

Serum Institute of India, under whose aegis the vaccine is to be being tried on 1,600 participants across 17 centres, said that trials in India will continue, irrespective of the latest development.

published on : 9th September 2020

Phase two trials of Oxford's COVID vaccine start in Mysuru hospital

The ICMR will collect 100 samples from across the country for further study and look into modifications.

published on : 30th August 2020

Phase 2 trial of Oxford COVID-19 vaccine candidate set to begin from Tuesday

Serum Institute of India has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, developed by the University of Oxford.

published on : 25th August 2020

If everything goes well India would get COVID-19 vaccine by year-end: Harsh Vardhan

Three COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India.

published on : 24th August 2020

Vaccine will be launched in India only after trials show positive results: Serum Institute

The clarification comes after some reports suggested that the experiment vaccine, developed by Oxford University, could be launched in 73 days.

published on : 24th August 2020
1 2 3 > 
IPL_2020